Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

0.3980 +0.0202 (+5.35%)
Streaming Delayed Price Updated: 10:43 AM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bluebird Bio

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.3% to $1.03 during Wednesday's after-market session. The company's market cap stands at $33.2 million. 
Via Benzinga
7 Oversold Stocks on the Verge of Blasting Off
Although terrible economic data has imposed a bloodbath in the market, certain oversold stocks are ripe for a potential comeback. 
Via InvestorPlace
Bluebird (BLUE) Stock Soars 25% Following 2 FDA Recommendations
Bluebird Bio (BLUE) stock is gaining on Monday following positive news last week from an advisory committee set up by the FDA. 
Via InvestorPlace
FDA Advisory Committee Backs Bluebird Bio's Blood Disorder Gene Therapy
Via Benzinga
Bluebird Bio Secures FDA Advisory Committee's Endorsement For Neurodegenerative Disease Drug
The U.S. 
Via Benzinga
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another
Via Benzinga
The 5 Top Profit & Protection Stocks to Buy for 2022
It's important to know which quantitative factors make a stock worthwhile. These five have the attributes needed for success. 
Via InvestorPlace
Dow Jones Turns Lower; Revlon Shares Jump
U.S. stocks pared gains midway through trading, with the Dow Jones dropping around 100 points on Friday. 
Via Benzinga
33 Stocks Moving In Friday's Mid-Day Session
Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy. 
Via Benzinga
U.S. Markets Open Higher; Dow Rises Around 200 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Friday. 
Via Benzinga
82 Biggest Movers From Yesterday
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
93 Biggest Movers From Yesterday
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
Mid-Afternoon Market Update: Gold Down Over 2%; Electric Last Mile Solutions Shares Plummet
U.S. stocks traded lower toward the end of trading, with the S&P 500 dropping by more than 3% on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic... 
Via Benzinga
Mid-Day Market Update: Nasdaq Dips Over 400 Points; Day One Biopharmaceuticals Shares Jump
U.S. stocks traded lower midway through trading, with the Nasdaq Composite tumbling by more than 400 points on Monday. 
Via Benzinga
70 Stocks Moving In Monday's Mid-Day Session
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; Dow Drops 600 Points
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 600 points on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers bluebird bio (NASDAQ:BLUE) shares rose 53.4% to $6.12 during Friday's after-market session. Trading volume for this security closed at 5.0 million, accounting for 206.3% of its average full-day... 
Via Benzinga
FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy
From bluebird bio, Inc.
Via Business Wire
bluebird bio stock trading halted today June 9th and tomorrow June 10th
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting
From bluebird bio, Inc.
Via Business Wire
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
These biotech stocks face some key make-or-break events in June that could have big implication for their futures. 
Via InvestorPlace
TC BioPharm Reports Racing Toward What Could Be A Major Cancer Immunotherapy Breakthrough
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.